Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#3510 Efficacy of 177- Lutetium DOTATATE Peptide Receptor Radionuclide Therapy in patients with metastatic NENs and carcinoid syndrome refractory to somatostatin analogues

Introduction: Optimal management of refractory carcinoid syndrome (RCS) represents an unmet clinical need in patients with metastatic Neuro Endocrine Neoplasms (NEN).

Conference:

Presenting Author: Ratnayake G

Authors: Ratnayake G, Koffas A, Theocharopoulos I, Hayes A, Navalkissoor S,

Keywords: carcinoid syndrome, PRRT,

#2097 Oral Ondansetron Offers Effective Symptomatic Bridging for Carcinoid Syndrome Refractory to Somatostatin Analogues

Introduction: Somatostatin analogues (SSA) are standard for symptomatic patients with neuroendocrine tumours (NETs). However, most patients experience tachyphylaxis, and limited options exist for this refractory carcinoid syndrome (RCS). Recently, ondansetron has been associated with reduction of bowel movement in a small series.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kiesewetter B

Authors: Kiesewetter B, Duan H, Haug A, Riss P, Selberherr A,

Keywords: carcinoid syndrome, ondansetron, 5-HT3 antagonist, neuroendocrine tumor, somatostatin, analogues,

#1363 Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues

Introduction: Somatostatin Analogues (SSAs) are considered the gold standard treatment in Neuroendocrine Tumours (NETs) and carcinoid syndrome.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Koffas A

Authors: Koffas A, Popat R, Dimitriou G, Quigley A, Navalkissoor S,

Keywords: PRRT, carcinoid syndrome,

#394 Efficacy of Telotristat Etiprate in Refractory Carcinoid Syndrome: Results of a Randomized, Placebo-controlled, Multicenter Study

Introduction: Diarrhea associated with carcinoid syndrome (CS) has been attributed to excess serotonin. Telotristat etiprate is an oral serotonin synthesis inhibitor that decreases peripheral serotonin production.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulke M, O'Dorisio T, Phan A, Bergsland E, Freiman J,

Keywords: carcinoid syndrome, telotristat etiprate,